2. Academic Validation
  3. Recent Advances in the Discovery of CK2 Inhibitors

Recent Advances in the Discovery of CK2 Inhibitors

  • ACS Omega. 2024 May 3;9(19):20702-20719. doi: 10.1021/acsomega.3c10478.
Mustafa A Al-Qadhi 1,  Tawfeek A A Yahya 2,  Hala B El-Nassan 3
Affiliations

Affiliations

  • 1 Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, 18084 Sana'a, Yemen.
  • 2 Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, 18084 Sana'a,Yemen.
  • 3 Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
PMID: 38764653 DOI: 10.1021/acsomega.3c10478
Abstract

CK2 is a vital Enzyme that phosphorylates a large number of substrates and thereby controls many processes in the body. Its upregulation was reported in many Cancer types. Inhibitors of CK2 might have Anticancer activity, and two compounds are currently under clinical trials. However, both compounds are ATP-competitive inhibitors that may have off-target side effects. The development of allosteric and dual inhibitors can overcome this drawback. These inhibitors showed higher selectivity and specificity for the CK2 Enzyme compared to the ATP-competitive inhibitors. The present review summarizes the efforts exerted in the last five years in the design of CK2 inhibitors.

Figures
Products